



## STEP THERAPY POLICY

**POLICY:** Nonsteroidal Anti-Inflammatory Drugs Step Therapy Policy

**REVIEW DATE:** 01/17/2024; selected revision 02/14/2024

**Note:** This list is not all-inclusive.

NSAID	Product	Manufacturer
<b>Diclofenac</b>	Cataflam® tablets (brand obsolete 11/17/2022)	Novartis, generic
	diclofenac sodium delayed-release tablets	Generic only
	Lofena™ tablets	Carwin, generic
	Voltaren® XR extended-release tablets (obsolete 03/01/2021)	Novartis, generic
	Zorvolex® capsules, authorized generic (35 mg only)	Iroko
	Zipsor® capsules	Assertio, generic
	Cambia® powder for oral solution	Assertio, generic
	Arthrotec® (diclofenac and misoprostol tablets)	Pfizer, generic
	diclofenac 1.5% solution	Generic only
	Flector® (diclofenac epolamine 1.3% topical patch)	Institut Biochimique, generic
	Licart™ (diclofenac epolamine 1.3% topical system)	Institut Biochimique
	Pennsaid® (diclofenac sodium 2% topical solution)	Horizon, generic
	Voltaren® Gel (diclofenac sodium 1% topical gel [brand obsolete 3/1/2021]) [ <b>OTC topical gel available</b> ]	Endo, generic
<b>Etodolac</b>	Lodine® tablets	Sallus, generic
	etodolac capsules	Generic only
	etodolac extended-release tablets	Generic only
<b>Fenoprofen</b>	Nalfon® capsules and tablets	Xspire, generic to tablets only
	Fenortho® capsules	Sterling Knight
	Fenoprofen capsules (brand)	Various
<b>Flurbiprofen</b>	flurbiprofen tablets	Generic only
<b>Ibuprofen</b>	ibuprofen capsules, tablets, and oral suspension [ <b>OTC capsules, tablets, chewable tablets, oral suspension available</b> ]	Generic only
	Duexis® (ibuprofen and famotidine tablets)	Horizon, generic
<b>Indomethacin</b>	indomethacin capsules and extended-release capsules	Generic only
	Indocin® oral suspension	Iroko, generic
	Tivorbex® capsules	Iroko, generic
<b>Ketoprofen</b>	ketoprofen capsules and extended-release capsules	Generic only
<b>Ketorolac</b>	ketorolac tablets	Generic only
	Sprix® (ketorolac nasal spray)	Egalet, generic
<b>Meclofenamate</b>	meclofenamate capsules	Generic only
<b>Mefenamic acid</b>	mefenamic acid capsules	Generic only
<b>Meloxicam</b>	Mobic® tablets (brand obsolete 4/1/2022)	Boehringer Ingelheim, generic
	Vivlodex™ capsules	Iroko, generic
	meloxicam oral suspension	Generic only
<b>Nabumetone</b>	Relafen® tablets (brand obsolete 11/17/2022)	Blucrest, generic
	Relafen® DS tablets	Carwin
<b>Naproxen</b>	Naprosyn® tablets and oral suspension [ <b>OTC tablets available</b> ]	Canton, generic
	EC-Naprosyn® delayed-release tablets	Canton, generic
	Anaprox DS® controlled-release tablets	Canton, generic
	Naprelan® controlled-release tablets	Almatica, generic

	Vimovo® (naproxen and esomeprazole delayed-release tablets)	Horizon, generic
<b>Oxaprozin</b>	Daypro® tablets	Pfizer, generic
	Coxanto® capsules	Solubiomix
<b>Piroxicam</b>	Feldene® capsules	Pfizer, generic
<b>Sulindac</b>	sulindac tablets	Generic only
<b>Tolmetin</b>	tolmetin capsules and tablets (product obsolete 11/8/2022)	Generic only

NSAID – Nonsteroidal anti-inflammatory drug; OTC – Over-the-counter.

### **INSTRUCTIONS FOR USE**

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

## **Cigna National Formulary Coverage:**

### **OVERVIEW**

Nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated primarily for the treatment of acute and chronic conditions that require an agent with analgesic and anti-inflammatory activity, although other uses exist.<sup>1</sup> For example, Cambia® (diclofenac potassium oral solution) is the only NSAID indicated for the acute treatment of migraine attacks with or without aura in adults ≥ 18 years of age<sup>2</sup>; however, other NSAIDs are also supported in clinical practice guidelines.<sup>3</sup>

Overall, it appears that NSAID products have similar clinical efficacy when given at equipotent doses for the management of acute pain and other pain-related conditions; however, individual responses to NSAIDs may vary among patients for reasons that are not well understood. No one product can be distinguished from another on a consistent basis. All of the products have Boxed Warnings outlining cardiovascular (CV) and gastrointestinal (GI) risks.<sup>1</sup>

### **Guidelines and Recommendations**

**The American College of Rheumatology (ACR)/Arthritis Foundation hand, hip, and knee osteoarthritis (OA) guidelines (2019)** strongly recommend topical NSAIDs for knee OA and conditionally recommend topical NSAIDs for hand OA.<sup>4</sup> Topical NSAIDs are not expected to be efficacious in hip OA due to the depth of the affected joint. Oral NSAIDs are strongly recommended for patients with

hand, hip, and/or knee OA and are recommended over all other oral therapies. These agents are the mainstay of pharmacological management of OA. Safe use of NSAIDs is recommended, including utilization of the lowest possible doses for the shortest period of time. The relative merits of different oral NSAIDs were considered outside the scope of the guideline review.

**The European League Against Rheumatism (EULAR) hand OA guidelines (2018)** state that optimal management of hand OA generally requires a multidisciplinary approach, including non-pharmacological therapies and pharmacological therapies.<sup>5</sup> The guidelines specifically recommend topical treatments as preferred over oral therapies because of safety reasons. Topical NSAIDs are the first pharmacological topical treatment of choice for hand OA. The guidelines cite pooled safety data comparing topical diclofenac gel with placebo, which showed similar low rates of adverse events (AEs) in subgroups of low-risk versus high-risk patients ( $\geq 65$  years of age with comorbid hypertension, type 2 diabetes or cerebrovascular and/or CV disease). The guidelines additionally note that when a large number of joints are affected, oral pharmacological treatment may be preferred.

**OA Research Society International guidelines for non-surgical management of knee, hip, and polyarticular OA (2019)** comment on oral and topical NSAID use in a variety of settings.<sup>6</sup> For knee OA, topical NSAIDs are strongly recommended (Level 1A) for patients without comorbidities, as well as for patients with GI or CV comorbidities. For patients with GI comorbidities, selective cyclooxygenase-2 (COX-2) inhibitors and nonselective oral NSAIDs, in combination with a proton pump inhibitor (PPI), were conditionally recommended due to their benefits on pain and functional outcomes. Topical and oral NSAIDs are both conditionally recommended in the setting of widespread pain; it is noted that for topical NSAIDs, the number of joints being treated should be monitored due to potential risk of exceeding recommended doses. Oral NSAIDs, but not topical NSAIDs, are conditionally recommended in the setting of hip OA.

### **Beers Criteria**

In 2023, the American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.<sup>7</sup> The Beers Criteria acknowledge that many nonselective NSAIDs increase the risk of GI bleeding or peptic ulcer disease in high-risk groups, which include patients  $> 75$  years of age or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents. It is noted that use of a PPI or misoprostol reduces but does not eliminate the risks. Indomethacin and ketorolac (including the parenteral formulation) should be avoided due to the increased risk of GI bleeding/peptic ulcer disease and acute kidney injury in older adults. Indomethacin is more likely to cause central nervous system AEs and appears to have the most AEs among the NSAIDs. NSAIDs and COX-2 inhibitors should be avoided in patients with symptomatic heart failure due to the potential to promote fluid retention and/or exacerbate heart failure. In patients with kidney or urinary tract disease (creatinine clearance  $< 30$  mL/min) it is noted that NSAIDs (non-COX and COX selective, oral and parenteral, nonacetylate salicylates) may

increase the risk of acute kidney injury and further decline in renal function. It is recommended to avoid these agents.

## **POLICY STATEMENT**

This program has been developed to encourage the use of two Step 1a Products prior to the use of a Step 2a Product. Of note, naproxen/esomeprazole delayed-release tablets (Vimovo, generic) and ibuprofen/famotidine tablets (Duexis, generic) are not included in Step 2a. A trial of one prescription naproxen product (Step 1b) and one prescription proton pump inhibitor (PPI) [Step 1b] is required prior to the use of naproxen/esomeprazole delayed-release tablets (Vimovo, generic) [Step 2b]. A trial of one prescription oral ibuprofen product (Step 1c) and one prescription oral histamine<sub>2</sub>-receptor antagonist (H<sub>2</sub>RA) [Step 1c] is required prior to the use of ibuprofen/famotidine tablets (Duexis, generic) [Step 2c]. If the Step Therapy rule is not met for a Step 2 Product (a, b, or c) at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

### **Step 1a/2a**

#### **Step 1a NSAIDs:**

- |                                       |  |                       |
|---------------------------------------|--|-----------------------|
| • Cataflam                            | • diclofenac sodium topical solution 1.5%* | • ketorolac (tablets) |
| • diclofenac potassium 50 mg          | • etodolac (IR and ER)                     | • meclofenamate       |
| • diclofenac potassium 25 mg capsules | • flurbiprofen                             | • mefenamic acid      |
| • diclofenac sodium (IR and ER)       | • ibuprofen                                | • meloxicam tablets   |
| • diclofenac sodium and misoprostol   | • indomethacin (IR and ER)                 | • nabumetone          |
|                                       | • ketoprofen IR 50 mg and 75 mg            | • naproxen**          |
|                                       |  | • oxaprozin           |
|                                       |  | • piroxicam           |
|                                       |  | • sulindac            |
|                                       |  | • tolmetin 200 mg     |

#### **Step 2a NSAIDs:**

- |  |   |                         |
|--|---|-------------------------|
| • Anaprox DS                                 | • Feldene   | • ketoprofen IR 25 mg   |
| • Arthrotec                                  | • Fenoprofen (brand), fenoprofen 600 mg           | • Licart*               |
| • Cambia, diclofenac potassium powder packet | • Fenortho  | • Lodine                |
| • Coxanto                                    | • Flector patch, diclofenac epolamine 1.3% patch* | • Lofena                |
| • Daypro                                     | • Indocin   | • meloxicam capsules    |
| • diclofenac potassium 25 mg tablets         | • indomethacin oral suspension                    | • meloxicam suspension  |
| • diclofenac sodium 1% topical gel*          | • ketoprofen ER 200 mg                            | • Mobic                 |
| • diclofenac sodium 2% topical solution*     |   | • Nalfon                |
|  |   | • Naprelan and generics |

- Naprosyn, EC-Naprosyn, and generic suspension
- Pennsaid 2%\*
- Qmiiz
- Relafen
- Relafen DS
- Sprix, ketorolac nasal spray
- Tivorbex, indomethacin 20 mg capsule
- tolmetin 400 mg, 600 mg
- Vivlodex
- Voltaren Gel 1%\*
- Voltaren XR
- Zipsor
- Zorvolex, diclofenac 35 mg capsule

IR – Immediate-release; ER – Extended-release

\* Denotes topical product

\*\* Some generic naproxen products are Step 2a

### **Step 1b/2b**

#### **Step 1b (brand or generic):**

- Prescription naproxen sodium
- Prescription naproxen

#### **AND**

- Prescription dexlansoprazole
- Prescription esomeprazole magnesium
- Prescription esomeprazole strontium
- Prescription lansoprazole
- Prescription omeprazole
- Prescription omeprazole magnesium
- Prescription omeprazole/sodium bicarbonate
- Prescription pantoprazole (oral)
- Prescription rabeprazole

#### **Step 2b NSAID:**

- Vimovo
- naproxen/esomeprazole delayed-release tablets

### **Step 1c/2c**

#### **Step 1c (brand or generic):**

- Prescription ibuprofen (oral)

#### **AND**

- Prescription cimetidine (oral)
- Prescription famotidine (oral)
- Prescription nizatidine (oral)
- Prescription ranitidine (oral)

#### **Step 2c NSAID:**

- Duexis
- ibuprofen/famotidine tablets

**Nonsteroidal Anti-Inflammatory Drugs product(s) is(are) covered as medically necessary when the following step therapy criteria is(are) met. Any other exception is considered not medically necessary.**

## **CRITERIA**

### **Step 2a NSAIDs**

- 1.** If the patient has tried two different Step 1a prescription-strength NSAIDs for the current condition, approve a Step 2a NSAID.

Note: Celecoxib is accepted as a generic NSAID. Also, over-the-counter (OTC) NSAIDs count as alternatives if the patient used prescription-strength doses.

- 2.** If the patient has tried ibuprofen suspension, approve naproxen suspension, meloxicam suspension, or Indocin suspension.

Note: OTC ibuprofen suspension would count as an alternative.

- 3.** If the patient has tried generic diclofenac sodium topical solution 1.5% and the patient has difficulty swallowing or cannot swallow tablets or liquid dosage forms (solution/suspension), approve ketorolac nasal spray (Sprix, authorized generic), Pennsaid 2%, diclofenac sodium 2% topical solution, Flector Patch, diclofenac epolamine 1.3% patch, Licart topical system, diclofenac sodium 1% topical gel, or Voltaren Gel.

- 4.** If the patient has tried generic diclofenac sodium topical solution 1.5% and the patient has a chronic musculoskeletal pain condition (e.g., osteoarthritis) and is at risk of NSAID-associated toxicity, approve Pennsaid 2%, diclofenac sodium 2% topical solution, diclofenac sodium 1% topical gel, or Voltaren Gel.

Note: Examples of risk factors of NSAID-associated toxicity include patients with a previous gastrointestinal bleed, history of peptic ulcer disease, impaired renal function, cardiovascular disease, hypertension, heart failure, elderly patients with impaired hepatic function, or taking concomitant anticoagulants.

- 5.** If the patient has tried generic diclofenac sodium topical solution 1.5% and the patient has hand or knee osteoarthritis, approve Pennsaid 2%, diclofenac sodium 2% topical solution, diclofenac sodium 1% topical gel, or Voltaren Gel.

### **Step 2b NSAID (Vimovo, generic)**

- 1.** If the patient has tried one prescription proton pump inhibitor (PPI) [e.g., omeprazole, lansoprazole, pantoprazole] and one prescription naproxen product (brand or generic), approve naproxen/esomeprazole delayed-release tablets (Vimovo, generic).

Note: Do not approve naproxen/esomeprazole delayed-release tablets (Vimovo, generic) if the patient has only tried over-the-counter (OTC) naproxen, NSAIDs other than naproxen, a COX-2 inhibitor (celecoxib), or OTC PPIs.

Note: Separate trials of a prescription PPI and a prescription naproxen product are required; a previous trial of Vimovo or generic naproxen/esomeprazole does not count.

### **Step 2c NSAID (Duexis, generic)**

1. If the patient has tried one prescription histamine<sub>2</sub>-receptor antagonist (H<sub>2</sub>RA) [e.g., famotidine, ranitidine, nizatidine] and one prescription ibuprofen product (brand or generic), approve ibuprofen/famotidine tablets (Duexis, generic).

Note: Do not approve ibuprofen/famotidine tablets (Duexis, generic) if the patient has only tried over-the-counter (OTC) ibuprofen, NSAIDs other than ibuprofen, a COX-2 inhibitor (celecoxib), or OTC H<sub>2</sub>RAs.

Note: Separate trials of a prescription H<sub>2</sub>RA and a prescription ibuprofen product are required; a previous trial of Duexis or generic ibuprofen/famotidine does not count.

### **REFERENCES**

1. Facts and Comparisons Online®. Wolters Kluwer Health, Inc.; Last updated September 1, 2023. Available at: <http://fco.factsandcomparisons.com/action/home>. Accessed on January 9, 2024. Search term: Nonsteroidal anti-inflammatory agents.
2. Cambia® oral solution [prescribing information]. Lake Forest, IL: Assertio; April 2021.
3. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019; 59:1-18.
4. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Rheumatol*. 2020; 72(2):220–233.
5. Kloppenburg M, Kroon F, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. *Ann Rheum Dis*. 2019; 78:16-24.
6. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage*. 2019; 27(11):1578-1589.
7. The American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2023;71(7):2052-2081.

### **HISTORY**

<b>Type of Revision</b>	<b>Summary of Changes</b>	<b>Review Date</b>
Annual Revision	No criteria changes.	04/12/2023
Early Annual Revision	<b>Coxanto:</b> Coxanto capsule was added to the Policy to Step 2a.	01/17/2024
Selected Revision	<b>Indomethacin suspension:</b> indomethacin oral suspension (generic Indocin suspension) was added to the Policy to Step 2a.	02/14/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.